Figure 1. Increase in CD4
+ T cell surface expression of glucocorticoidinduced tumor necrosis factor receptor family-related (GITR) protein at baseline and impairment of phytohemagglutinin (PHA) induction of additional GITR expression in HIV-infected subjects. Panel A shows a representative plot in which the surface expression of GITR after PHA simulation is shaded. Panel B shows results for 6 HIV-negative and 8 HIV-positive subjects; the percentage of CD4 + T cells expressing GITR after PHA stimulation is shaded. Groups were compared using the MannWhitney U test. Error bars show SDs. NS, not significant.
Although triggering other members of the TNF receptor family has been explored as a means of heightening immune responses to HIV [24] [25] [26] [27] , the role played by GITR triggering in enhancing cellular immune responses to HIV or in protecting HIV-specific effector T cells from apoptosis has not been explored. However, GITR triggering has been shown to reverse effector T cell impairment during murine retroviral infection [28] and to intensify murine responses a retroviral vaccine when administered in conjunction with soluble CD40 ligand [29] .
Accordingly, we hypothesized that GITR triggering would enhance HIV-specific CD4 + T cell responses by protecting HIVspecific CD4 + T cells from apoptosis. To test this hypothesis, we characterized the impact of HIV infection on GITR expression on CD4 + T cells and examined the impact of GITR triggering with a monoclonal antibody on HIV-specific CD4 + T cell cytokine expression and on apoptosis of HIV-specific CD4 + T cells.
METHODS
Subjects and cell isolation. HIV-infected adults and uninfected control subjects gave informed consent to donate whole blood in a research protocol approved by the Dartmouth College Committee for the Protection of Human Subjects. Peripheral blood mononuclear cells (PBMCs) were isolated by ficoll density gradient centrifugation and were cultured in RPMI 1640 supplemented with penicillin, streptomycin, HEPES buffer, l-glutamine, and 10% fetal calf serum. Antibodies and cell subsets. PBMCs were stained with fluorochrome-conjugated monoclonal antibodies against CD3 and CD4 or CD8 (BD Biosciences). T cells were defined as CD3 + cells within the lymphocyte cloud on a forward scatter-side scatter plot. All analyses were conducted on T cells expressing CD4 or CD8.
Inducible GITR expression on CD4 + T cells. PBMCs were incubated for 2 h at 37ЊC in 5% CO 2 in either medium alone or medium plus phytohemagglutinin (PHA; Sigma), and the percentage of CD4 + T cells expressing surface GITR was characterized using a fluorochrome-conjugated monoclonal antibody (R&D Systems). Specificity of staining was confirmed using an isotype control.
Antigens. [30] . Briefly, after antigen stimulation for 2 h aided by antibodies against CD28 and CD49d, brefeldin A was added for 5 h to trap expressed cytokines in cells, and then a standard fixation and permeabilization protocol was used to stain cells after overnight refrigeration (Caltag). Intracellular caspase-3 staining. Freshly isolated PBMCs from HIV-infected subjects not receiving antiretroviral therapy were stimulated for 2 h with experimental and control antigens, incubated for 5 h with brefeldin A, and then refrigerated overnight before cells were stained for surface expression of CD3 and CD4 and for intracellular expression of TNF-a and activated caspase-3 (BD Biosciences) using a standard fixation, permeabilization, and staining protocol (Caltag). SEB (Sigma) was used as a positive control for intracellular TNF-a staining, and monoclonal antibodies against CD95 (Upstate) were used as a positive control for the detection of apoptosis. An isotype control antibody was used to confirm the GITR specificity of the effects of anti-GITR antibodies.
Statistical analysis. CD4 + T cell expression of GITR was compared between conditions using a Mann-Whitney U test, as was the percentage of CD4 + T cells expressing intracellular activated caspase-3. The percentage of CD4 + or CD8 + T cells expressing intracellular cytokines in multiple subjects was compared in pooled samples using the Wilcoxon test. The correlation between the magnitude of the impact of GITR triggering and CD4 + T cell counts and serum HIV loads as well as antiretroviral treatment status was measured using a Pearson x 2 test. All analyses were conducted using Prism software (version 4; GraphPad).
RESULTS

Increase in baseline CD4
+ T cell expression of GITR and impairment of PHA-induced GITR expression during HIV infection. To characterize the impact of HIV infection on GITR expression, CD4 + T cells were stained for GITR before and after PHA stimulation of PBMCs from 8 HIV-infected subjects and 6 HIV-uninfected control subjects (average age, 42.5 and 45.2 years, respectively;
). The percentage of P p .647 CD4 + T cells expressing surface GITR was greater at baseline in the HIV-infected subjects than in the control subjects (mean, 34.70% vs. 10.59%; ) (figure 1A). PHA stimulation P p .035 increased surface expression of GITR in the control subjects (mean, 10.59% vs. 51.30%; ) but not in the HIV-P p .032 infected subjects (mean, 34.70% vs. 45.03%; ) (figure P p .402 1B). PHA-stimulated GITR expression was not different between the HIV-infected subjects and the control subjects (mean, 45.03% vs. 51.30%;
). P p 1.000 Enhancement of HIV p55-specific CD4 + T cell cytokine secretion by GITR triggering. We tested the hypothesis that antibody triggering of GITR would enhance HIV-specific cytokine secretion by comparing the percentage of CD4 + and CD8 + T cells expressing intracellular TNF-a and IFN-g to HIV p55 and other antigens via intracellular cytokine staining. HIV p55-specific CD4 + T cell expression of both TNF-a and IFNg was enhanced by GITR triggering, whereas GITR triggering alone or with pooled CEF peptides induced little additional expression of TNF-a and IFN-g ( figure 2A ). We then studied the impact of GITR triggering on HIV-specific cytokine secretion in 12 subjects with chronic HIV infection. The mean age of these subjects was 46 years, 10 were male, and 9 were receiving antiretroviral therapy; the mean CD4 + T cell count was 356 cells/mL, and the mean HIV load was 51,208 copies/mL. GITR triggering significantly increased the percentage of CD4 + T cells expressing HIV p55-specific TNF-a (mean, 0.51% vs. 1.00%; ) (figure 2B) and IFN-g expression (mean, P p .008 0.37% vs. 0.51%; ) (figure 2C). Antibody triggering P p .034 of GITR did not alter HIV p55-specific CD8 + T cell expression of TNF-a (mean, 0.79% vs. 0.59%; ) ( figure 2D ) or P p .765 IFN-g (mean, 0.63% vs. 0.56%; ) (figure 2E). CEF-P p .542 specific T cell responses were unaffected by GITR triggering (figure 2B-2E). GITR triggering did not change the percentage of HIV-specific T cells exhibiting dual cytokine secretion (data not shown).
Correlation between the increase in HIV-specific CD4 + T cell expression of TNF-a after GITR triggering and peripheral CD4 + T cell count. To determine whether clinical progression of HIV infection impacts CD4 + T cell responsiveness to GITR triggering, we assessed the correlation between the peripheral CD4 + T cell count and the magnitude of the increase in the percentage of CD4 + T cells expressing TNF-a after GITR triggering in PBMCs from 12 HIV-infected subjects. The increase in the percentage of HIV p55-specific CD4 + T cells expressing intracellular TNF-a after GITR triggering correlated directly with peripheral absolute CD4 + T cell count ( ; Pearson P p .009 ) (figure 3) but not with plasma viral load ( R p 0.714 P p + T cell responses to HIV p55 but not to CEF and because GITR triggering has been shown to protect T cells from apoptosis in murine models [20] [21] [22] [23] , we tested the hypothesis that GITR triggering enhances HIV-specific CD4 + T cell cytokine secretion by protecting HIV-specific CD4 + T cells from apoptosis. To avoid confounding, we studied the impact of GITR triggering on apoptosis in HIV-specific CD4 + T cells from patients not receiving antiretroviral therapy. Simultaneous intracellular expression of TNF-a and activated caspase-3 by CD4 + T cells was assessed in unfractionated PBMCs from HIV-infected subjects with viremia after stimulation with control medium, HIV p55, or pooled CEF peptides with and without GITR triggering. Intracellular expression of activated caspase-3 was greater in TNF-a-expressing CD4 + T cells after stimulation with HIV p55, compared with that in unstimulated cells (mean, 12.15% vs. 7.41%; ) (figure 4A). Intracellular expression P ! .001 of activated caspase-3 was not, however, increased in CD4 + T cells responding to CEF (mean, 10.22% vs. 7.41%;
). P p .200 Furthermore, activated caspase-3 expression was significantly reduced after GITR triggering in CD4 + T cells expressing TNFa to HIV p55 (mean, 12.15% vs. 10.45%; ) (figure 4B) P ! .001 but not in CEF-specific CD4 + T cells (mean, 10.22% vs. 9.76%; ). By contrast, GITR triggering had no impact on the P p 1.000 intracellular expression of caspase-3 in CD4 + T cells not expressing TNF-a. Furthermore, isotype control antibody had no effect on intracellular caspase-3 expression in any experimental condition.
DISCUSSION
HIV-specific, HIV-infected, and bystander CD4 + T cells undergo dramatic and progressive apoptotic deletion during the course of HIV infection [1, 4, 5, 7-9, 31, 32] . Our data show that, despite abnormal GITR expression on CD4 + T cells during HIV infection, GITR triggering protects HIV-specific CD4 + T cells from apoptosis and enhances HIV-specific CD4 + T cell cytokine secretion.
GITR, a member of the TNF receptor family, is expressed transiently on antigen-specific and activated lymphocytes [16, 17, 23] , and, in the healthy host, GITR triggering potentiates effector T cell responses [19, 21, 22] . Other members of the TNF receptor family of cell surface molecules, such as OX40, 4-1BB, and herpesvirus entry mediator (HVEM), also are involved in modulating and sustaining antigen-specific T cell responses [24] , and OX40 and 4-1BB triggering has been shown to modulate HIV-specific T cell responses [25] [26] [27] . Our data extend prior findings that GITR triggering can enhance murine immune responses to retroviruses or retroviral vaccines [28, 29] by showing that GITR triggering enhances HIV-specific CD4 + T cell cytokine secretion in humans. GITR is therefore a member of the TNF receptor family that will be important to further explore in novel approaches to HIV immunotherapy.
Maximal baseline GITR expression in HIV-infected individuals may signify the induction of a protective host response against HIV infection, perhaps in response to the chronic immunological activation of HIV infection. This maximal baseline induction of GITR expression in HIV-infected subjects likely explains why additional induction of GITR expression with even a potent immunological stimulus was impaired. Analogous abnormalities of the expression of other costimulatory molecules, such as CD40 ligand and cytotoxic T lymphocyte antigen 4, have been reported in HIV infection [33] [34] [35] .
Highly active antiretroviral therapy reduces apoptosis of HIV-specific T cells, as does PD-1 ligation, stimulation with IL-15, and inhibition of proapoptotic intracellular pathways [4, [10] [11] [12] [13] [14] [15] . However, GITR triggering represents a novel means of preventing apoptosis of CD4 + T cells, one that appears to have a preferential impact on HIV-specific CD4 + T cells. It will be interesting to explore whether GITR triggering and antiretroviral therapy have synergistic effects on CD4 + T cell apoptosis. Our data do not demonstrate a restoration of HIV-specific CD8 + T cell cytokine secretion after antibody triggering of GITR. It is possible that CD4 + T cells were at greater risk for apoptotic deletion during HIV infection and, thus, GITR triggering produced a preferential augmentation in cytokine secretion and protection from apoptosis in this cell population. Furthermore, restoration of CD4 + T cell help for CD8 + T cells may restore CD8 + T cell responses over a longer period of time than was assayed in the brief in vitro assays used in this study [36, 37] . Another possibility is that CD4 + and CD8 + T cell responses are impacted differentially by GITR triggering, a pattern that has been observed in other models [38] . CD4 + CD25 + regulatory T (T reg ) cells express GITR, as do activated T cells [17] . In murine models, triggering GITR abrogated T reg cell suppression of effector T cell responses [19, 21, 39] . However, in humans, GITR triggering may not relieve T reg cell suppression of effector T cell responses [40] . Given that CD4 + CD25 + T cells are infected by HIV [41] [42] [43] , modulate HIV-specific cellular immune responses [44, 45] , are depleted by HIV infection [46, 47] , and are dysfunctional during HIV infection [46, 48] , it will be interesting to explore whether GITR triggering impacts T reg cell modulation of HIV-specific cellular immune responses or HIV infection of CD4 + CD25 + T cells. GITR triggering is a novel and modifiable host protective mechanism against CD4 + T cell deletion during HIV infection. Thee present data support additional investigations into the role played by GITR triggering in the modulation of HIVspecific cellular immune responses and in the protection of HIV-specific CD4 + T cells from apoptosis.
